Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MYRIAD GENETICS INC
Report date November 03, 2025 · Filed November 04, 2025
Section 16 reporting ended · disclosed 2025-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 127,726 |
Reported balance
Holding disclosure · report date 2025-11-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 127,726 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2025 Filed Sep 22, 2025 20:14 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 958 | $7.77 | $7,443.66 |
DisclosureSEC source: 0001843568-25-000006 · wk-form4_1758572042.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · EVP, Strategy & Transformation 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,726 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 19, 2025. Read SEC document |
| March 22, 2025 Filed Mar 25, 2025 20:17 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,904 | $10.01 | $19,059.04 |
DisclosureSEC source: 0001628280-25-014730 · wk-form4_1742933838.xml · nonDerivative · entry 2 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,684 F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 21, 2025. Read SEC document |
| March 22, 2025 Filed Mar 25, 2025 20:17 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 718 | $10.01 | $7,187.18 |
DisclosureSEC source: 0001628280-25-014730 · wk-form4_1742933838.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,588 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 21, 2025. Read SEC document |
| March 15, 2025 Filed Mar 17, 2025 20:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,572 | $10.07 | $15,830.04 |
DisclosureSEC source: 0001628280-25-013153 · wk-form4_1742242824.xml · nonDerivative · entry 3 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,306 F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 14, 2025. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 20:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,417 | $10.07 | $34,409.19 |
DisclosureSEC source: 0001628280-25-013153 · wk-form4_1742242824.xml · nonDerivative · entry 2 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,878 F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 14, 2025. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 20:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 54,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-013153 · wk-form4_1742242824.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,295 F1 · shares: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 21:24 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,697 | $11.74 | $31,662.78 |
DisclosureSEC source: 0001843568-25-000002 · wk-form4_1740605078.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,703 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on February 25, 2025. Read SEC document |
| February 07, 2025 Filed Mar 5, 2025 00:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 6,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010139 · wk-form4_1741134703.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,171 F1 · shares: Consists of performance-based restricted stock units (PSUs) initially granted on March 22, 2022, subject to accomplishment of pre-determined performance metrics. On February 7, 2025, the Compensation and Human Capital Committee of the Company's Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 22, 2025. Read SEC document |
| September 21, 2024 Filed Sep 23, 2024 20:17 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 966 | $27.64 | $26,700.24 |
DisclosureSEC source: 0001843568-24-000006 · wk-form4_1727122641.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,400 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 20, 2024. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 11,538 | $27.82 | $320,987.16 |
DisclosureSEC source: 0001843568-24-000004 · wk-form4_1724444186.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,366 Read SEC document |
| March 22, 2024 Filed Mar 25, 2024 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 730 | $22.24 | $16,235.20 |
DisclosureSEC source: 0001628280-24-012918 · wk-form4_1711398698.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,904 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2024. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 20:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,585 | $21.16 | $33,538.60 |
DisclosureSEC source: 0001628280-24-011686 · wk-form4_1710794750.xml · nonDerivative · entry 2 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,634 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 15, 2024. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 20:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 35,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-011686 · wk-form4_1710794750.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,219 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 25, 2024 Filed Feb 26, 2024 21:09 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,231 | $22.72 | $50,688.32 |
DisclosureSEC source: 0001843568-24-000002 · wk-form4_1708981775.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,041 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on February 23, 2024. Read SEC document |
| September 21, 2023 Filed Sep 22, 2023 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001843568-23-000004 · wk-form4_1695414680.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,272 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 20:29 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 751 | $22.91 | $17,205.41 |
DisclosureSEC source: 0001628280-23-009054 · wf-form4_167960337427659.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,272 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2023. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 20:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 16,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-008325 · wf-form4_167899873690419.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,023 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 25, 2023 Filed Feb 27, 2023 21:11 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,556 | $18.54 | $47,388.24 |
DisclosureSEC source: 0001843568-23-000001 · wf-form4_167753224751902.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP, Chief of Staff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,604 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on February 24, 2023. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 21:01 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 9,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001843568-22-000004 · edgardoc.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,160 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 21:58 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,594 | $24.69 | $64,045.86 |
DisclosureSEC source: 0001843568-22-000002 · edgardoc.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,406 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person on February 18, 2021. The restricted stock units granted on February 18, 2021 represent a contingent right to receive one share of the Company's common stock and vested 25% on February 25, 2022 and vests 25% on February 25, 2023, 25% on February 25, 2024, and 25% on February 25, 2025. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on February 25, 2022. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001843568-21-000006 · edgardoc.xml · nonDerivative · entry 1 Ancona Margaret · CIK 0001843568 · SVP Enterprise Transformation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on February 18, 2022, 25% on February 18, 2023, 25% on February 18, 2024, and 25% on February 18, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.